Hypothesis

Aged c-Kit+ cardiac progenitor cells (CPCs) release mitochondria-derived exosomes that carry damaged mtDNA and oxidative stress signals. These exosomes are taken up by neighboring quiescent c-Kit+ CPCs, activating the cytosolic DNA-sensing cGAS-STING pathway and driving a secondary wave of senescence that exceeds the burden explained by telomere attrition or ROS alone.

Mechanistic Rationale

• Senescent CPCs exhibit mitochondrial dysfunction and increased PANoptosis, which promotes the shedding of mitochondria‑laden exosomes (3).
• Exosomal mtDNA, when sensed by cGAS in recipient cells, triggers STING‑dependent IFN‑β production and NF‑κB activation, amplifying SASP secretion (6).
• This paracrine loop creates a feed‑forward circuit where even CPCs with intact telomeres acquire senescence markers (p16INK4A, SA‑β‑gal) and lose cardiomyogenic potential.
• Inhibiting mitochondrial fission (e.g., with Mdivi‑1) should reduce exosome biogenesis, thereby breaking the loop and preserving the quiescent reservoir.

Testable Predictions

1. Exosome isolation from senescent CPC cultures will contain higher mtDNA copy number and 8‑oxoguanine lesions compared with exosomes from young CPCs.
2. In vitro uptake of these exosomes by quiescent c-Kit+ CPCs will increase cGAS phosphorylation, STING translocation, and SASP expression (IL‑6, MMP‑9) within 6 h.
3. Pharmacological blockade of mitochondrial fission (Mdivi‑1) or genetic knockdown of DRP1 in aged mouse hearts will decrease exosome release, lower cGAS‑STING activity in c-Kit+ cells, and improve cardiomyogenic potential after MI.
4. Rescue experiment: Adding purified exosomes from senescent CPCs to young CPC cultures will recapitulate senescence phenotypes, an effect abolished by pre‑treating exosomes with DNase I or using cGAS‑KO recipient cells.

Experimental Approach

• Isolation & characterization: Harvest CPCs from young (3 mo) and aged (24 mo) mice, induce senescence with doxorubicin, isolate exosomes via ultracentrifugation, quantify mtDNA (qPCR) and oxidative lesions (ELISA for 8‑oxo‑dG).
• Functional assays: Label exosomes with PKH67, co‑culture with GFP‑labelled quiescent CPCs, measure cGAS‑STING activation (Western blot for p‑TBK1, p‑IRF3) and SASP (multiplex cytokine array). Assess cardiomyogenic differentiation (α‑actinin+, troponin T+) after 7 days.
• In vivo validation: Treat aged mice with Mdivi‑1 (50 mg/kg/day, i.p.) for 2 weeks post‑MI, assess exosome plasma levels (NTA), cGAS‑STING signaling in sorted c‑Kit+ cells (flow cytometry), fibrosis (Masson’s trichrome), and ejection fraction (echocardiography).
• Controls: Use cGAS‑KO bone‑marrow chimeric mice, exosome‑depleted supernatants, and DNase‑I‑treated exosomes to confirm mtDNA specificity.

Potential Impact

If validated, this hypothesis would reveal a transmissible senescence mechanism that operates independently of telomere shortening, offering a new therapeutic angle: targeting mitochondrial exosome biogenesis or the cGAS‑STING axis to protect the endogenous c‑Kit+ reservoir. It also explains why senolytics alone may not fully restore regeneration in aged hearts—they remove the source but do not block the exosome‑mediated propagation of damage to surviving progenitors.